The RSK1/RSK2-specific inhibitor SL0101 [31,43], as well as RSK1-targeted or RSK2-targeted siRNA, were able to reduce the phosphorylation of YB-1 at S102 even following induction by the classic tumour promoter PMA. This evidence concerns the gene RPS6KA3 and neoplasm.